News
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...
The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...
Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted priority review for its request ...
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On July 2, Merck & Co., Inc. ...
1d
Dealbreaker on MSNMerck Breathes Life Into Its Respiratory Prospects With $10B Deal to Buy Verona PharmaVerona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...
The US Food and Drug Administration (FDA) has accepted for review Merck & Co’s New Drug Application (NDA) for ...
If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...
Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...
Merck & Co. said the U.S. Food and Drug Administration will review its application seeking approval of its proposed doravirine/islatravir regimen in certain adults with HIV-1 infection.
US pharma giant Merck & Co today revealed that the US Food and Drug Administration (FDA) has accepted and granted priority ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results